TrialEuropean heart journal2016

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.

Helen M Colhoun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.